Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Novavax, Inc. (NVAX)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$10.65+10.02%
Close 2026-11-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for NVAX yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Target 2026 R&D and SG&A expenses of $325M | A supporting condition in Novavax, Inc.'s published investment case. The stated target is <= $325M combined R&D and SG&A expenses. | Intact | Combined R&D and SG&A expenses exceed $325M in FY26 | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making biotech with a partnership-led growth thesis, not a proven durable compounder. The long-term thesis is intact after recent positive earnings events, but confidence is medium and execution remains mixed.
The valuation evidence is mixed: NVAX is described as cheap versus peers, while another measure shows a 43% premium versus peers. The expectations gap is negative, but model confidence is low, so the valuation signal is uncertain; the snapshot says weak execution quality is reflected, but not a broader expensive, weak, and turbulent setup.
Near term, recent results and the raised guidance support the thesis, while the Sanofi partnership has generated over $1 billion in revenue and added a $125 million milestone. Cost control is progressing, with 2026 expense guidance maintained and lower year-over-year net R&D expense in the second quarter, but the full-year outcome is not yet known. Earnings quality remains fragile, and a guidance cut or weaker economic conditions would add risk.
Over the next one to three years, a key test is whether Novavax expands Matrix-M partnerships and turns stated priorities into continued delivery. Progress toward clinical entry for the C. difficile candidate is another swing factor, though substantive clinical delivery remains limited so far. Near term, guidance credibility and broader healthcare-sector momentum could shape the business backdrop.
The multi-year view is intact, supported by partnership progress and recent results, but it remains a high-risk thesis with mixed execution and loss-making fundamentals. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| The company secured a licensing deal with Pfizer for Matrix-M, supporting future revenue. |
| Intact |
| Loss or termination of Matrix-M licensing agreement with Pfizer |
License active vs active target Jan 2026 license signed; Sep 2026 headlines confirm active Pfizer partnership and Matrix-M licensing momentum. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Achieve 2026 revenue of $230M-$270M | A primary condition in Novavax, Inc.'s published investment case. The stated target is >= $230M revenue. | Intact | Revenue falls below $230M in FY26 | Revenue: $56.698M FY2026-Q2; GAAP. Published target: >= $230M revenue. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 202656,698,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.27 → $-0.03 · observed estimates
$0.26B → $0.30B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.27 | $257,226,069 | 7 / 7 |
| 2026-07-25 | $-0.25 | $258,467,510 | 9 / 9 |
| 2026-07-26 | $-0.25 | $258,467,510 | 9 / 9 |
| 2026-07-27 | $-0.27 | $257,226,069 | 7 / 7 |
| 2026-07-28 | $-0.25 | $258,467,510 | 9 / 9 |
| 2026-07-29 | $-0.25 | $258,467,510 | 9 / 9 |
| 2026-07-30 | $-0.25 | $258,467,510 | 9 / 9 |
| 2026-07-31 | $-0.25 | $258,467,510 | 9 / 9 |
| 2026-08-01 | $-0.27 | $257,226,069 | 7 / 7 |
| 2026-08-02 | $-0.25 | $258,467,510 | 9 / 9 |
| 2026-08-03 | $-0.25 | $258,467,510 | 9 / 9 |
| 2026-08-04 | $-0.25 | $258,467,510 | 9 / 9 |
| 2026-08-05 | $-0.18 | $258,467,510 | 9 / 9 |
| 2026-08-06 | $-0.18 | $258,467,510 | 9 / 9 |
| 2026-08-07 | $-0.18 | $272,226,069 | 7 / 7 |
| 2026-08-08 | $-0.11 | $269,834,170 | 8 / 9 |
| 2026-08-09 | $-0.11 | $269,834,170 | 8 / 9 |
| 2026-08-10 | $-0.11 | $269,834,170 | 8 / 9 |
| 2026-08-12 | $-0.16 | $266,174,810 | 8 / 9 |
| 2026-08-13 | $-0.18 | $272,226,069 | 7 / 7 |
| 2026-08-14 | $-0.18 | $272,226,069 | 7 / 7 |
| 2026-08-15 | $-0.18 | $272,226,069 | 7 / 7 |
| 2026-08-16 | $-0.18 | $272,226,069 | 7 / 7 |
| 2026-08-17 | $-0.18 | $272,226,069 | 7 / 7 |
| 2026-08-18 | $-0.18 | $272,226,069 | 7 / 7 |
| 2026-08-19 | $-0.18 | $272,226,069 | 7 / 7 |
| 2026-08-20 | $-0.15 | $269,037,946 | 8 / 7 |
| 2026-08-21 | $-0.15 | $269,037,946 | 8 / 7 |
| 2026-08-22 | $-0.15 | $269,037,946 | 8 / 7 |
| 2026-08-23 | $-0.15 | $269,037,946 | 8 / 7 |
| 2026-08-24 | $-0.15 | $269,037,946 | 8 / 7 |
| 2026-08-25 | $-0.15 | $269,037,946 | 8 / 7 |
| 2026-08-26 | $-0.15 | $269,037,946 | 8 / 7 |
| 2026-08-27 | $-0.15 | $269,037,946 | 8 / 7 |
| 2026-08-28 | $-0.15 | $269,037,946 | 8 / 7 |
| 2026-08-29 | $-0.15 | $269,037,946 | 8 / 6 |
| 2026-08-30 | $-0.15 | $269,037,946 | 8 / 6 |
| 2026-08-31 | $-0.15 | $269,037,946 | 8 / 6 |
| 2026-09-01 | $-0.15 | $269,037,946 | 8 / 6 |
| 2026-09-02 | $-0.15 | $269,037,946 | 8 / 6 |
| 2026-09-03 | $-0.15 | $269,037,946 | 8 / 6 |
| 2026-09-04 | $-0.15 | $269,037,946 | 8 / 6 |
| 2026-09-05 | $-0.15 | $269,037,946 | 8 / 6 |
| 2026-09-06 | $-0.15 | $269,037,946 | 8 / 6 |
| 2026-09-07 | $-0.15 | $269,037,946 | 8 / 6 |
| 2026-09-08 | $-0.15 | $269,037,946 | 8 / 6 |
| 2026-09-09 | $-0.15 | $269,037,946 | 8 / 6 |
| 2026-09-10 | $-0.15 | $269,037,946 | 8 / 6 |
| 2026-09-11 | $-0.15 | $269,037,946 | 8 / 6 |
| 2026-09-12 | $-0.15 | $269,037,946 | 8 / 6 |
| 2026-09-13 | $-0.15 | $269,037,946 | 8 / 6 |
| 2026-09-14 | $-0.15 | $269,037,946 | 8 / 6 |
| 2026-09-15 | $-0.15 | $269,037,946 | 8 / 6 |
| 2026-09-16 | $-0.15 | $269,037,946 | 7 / 6 |
| 2026-09-17 | $-0.15 | $269,037,946 | 7 / 6 |
| 2026-09-18 | $-0.15 | $269,037,946 | 7 / 6 |
| 2026-09-19 | $-0.15 | $269,037,946 | 7 / 6 |
| 2026-09-20 | $-0.15 | $269,037,946 | 7 / 6 |
| 2026-09-21 | $-0.15 | $269,037,946 | 7 / 6 |
| 2026-09-22 | $-0.15 | $269,037,946 | 7 / 6 |
| 2026-09-23 | $-0.15 | $269,037,946 | 7 / 6 |
| 2026-09-24 | $-0.15 | $269,037,946 | 7 / 6 |
| 2026-09-25 | $-0.15 | $269,037,946 | 7 / 6 |
| 2026-09-26 | $-0.15 | $277,237,946 | 7 / 6 |
| 2026-09-27 | $-0.15 | $277,237,946 | 7 / 6 |
| 2026-09-28 | $-0.15 | $277,237,946 | 7 / 6 |
| 2026-09-29 | $-0.15 | $277,237,946 | 7 / 6 |
| 2026-09-30 | $-0.15 | $277,237,946 | 7 / 6 |
| 2026-10-01 | $-0.15 | $277,237,946 | 7 / 6 |
| 2026-10-02 | $-0.15 | $277,237,946 | 7 / 6 |
| 2026-10-03 | $-0.15 | $277,237,946 | 7 / 6 |
| 2026-10-04 | $-0.15 | $277,237,946 | 7 / 6 |
| 2026-10-05 | $-0.15 | $277,237,946 | 7 / 6 |
| 2026-10-06 | $-0.15 | $277,237,946 | 7 / 6 |
| 2026-10-07 | $-0.17 | $277,237,946 | 7 / 6 |
| 2026-10-08 | $-0.02 | $303,352,232 | 7 / 6 |
| 2026-10-09 | $-0.02 | $303,352,232 | 7 / 6 |
| 2026-10-10 | $0.03 | $317,213,525 | 7 / 6 |
| 2026-10-11 | $0.03 | $317,213,525 | 7 / 6 |
| 2026-10-12 | $0.03 | $317,213,525 | 7 / 6 |
| 2026-10-13 | $0.03 | $317,213,525 | 7 / 6 |
| 2026-10-14 | $0.03 | $317,213,525 | 7 / 6 |
| 2026-10-15 | $0.03 | $317,213,525 | 7 / 6 |
| 2026-10-16 | $0.03 | $317,213,525 | 7 / 6 |
| 2026-10-17 | $0.03 | $317,213,525 | 7 / 6 |
| 2026-10-18 | $0.03 | $311,633,713 | 7 / 6 |
| 2026-10-19 | $0.03 | $311,633,713 | 7 / 6 |
| 2026-10-20 | $0.03 | $311,633,713 | 7 / 6 |
| 2026-10-21 | $0.03 | $311,633,713 | 7 / 6 |
| 2026-10-22 | $0.03 | $311,633,713 | 7 / 6 |
| 2026-10-23 | $0.03 | $311,633,713 | 7 / 6 |
| 2026-10-24 | $0.03 | $311,633,713 | 7 / 6 |
| 2026-10-25 | $0.03 | $311,633,713 | 7 / 6 |
| 2026-10-26 | $0.03 | $311,633,713 | 7 / 6 |
| 2026-10-27 | $0.03 | $311,633,713 | 7 / 6 |
| 2026-10-28 | $0.08 | $322,347,998 | 7 / 6 |
| 2026-10-29 | $-0.03 | $301,633,713 | 7 / 6 |
| 2026-10-30 | $-0.03 | $301,633,713 | 7 / 6 |
| 2026-10-31 | $-0.03 | $301,633,713 | 7 / 6 |
| 2026-11-01 | $-0.03 | $301,633,713 | 7 / 6 |
| 2026-11-02 | $-0.03 | $301,633,713 | 7 / 6 |
| 2026-11-03 | $-0.03 | $301,633,713 | 7 / 6 |
| 2026-11-04 | $-0.03 | $301,633,713 | 7 / 6 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 5 Buy / Strong Buy · 1 Hold · 3 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 1 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.